Jennifer Y Sheng1,2, Cesar A Santa-Maria3, Amanda L Blackford3, David Lim3, Ashley Carpenter3, Karen L Smith3, Gary I Cohen4, Janelle Coughlin5, Lawrence J Appel5,6, Vered Stearns3, Claire Snyder3,6. 1. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. jsheng7@jhmi.edu. 2. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans St, Cancer Research Building 1, Room 142, Baltimore, MD, 21287, USA. jsheng7@jhmi.edu. 3. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4. Great Baltimore Medical Center, Baltimore, MD, USA. 5. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
PURPOSE: In pre-planned observational analysis of the POWER-remote trial, we examined the impact of weight loss on patient-reported outcomes (PROs). We hypothesized a priori that survivors with ≥ 5% weight loss would have improved physical function (PF) at 6 months vs. those who did not. METHODS: Patients with stage 0-III breast cancer who completed local therapy and chemotherapy with BMI ≥ 25 kg/m2 were randomized to POWER-remote (telephone coaching; diet/activity tracking) or self-directed weight loss (booklet). Participants completed PROs at baseline, 6, and 12 months: PROMIS PF, pain, fatigue, anxiety, depression, sleep; FACT-endocrine symptoms; MOS-sexual function. Changes in PROs among those with ≥ 5% weight loss vs. those with < 5% were tested with multivariable mixed effect models, across randomized groups. RESULTS: Of 94 women who completed PROs, 84 and 69 participants were evaluable at 6 and 12 months, respectively. Regardless of intervention, PF improved in those with ≥ 5% weight loss vs. those with < 5% at 6 months (4.4 vs. 0.3 points; p = 0.02) and 12 months (3.6 vs. 0 points; p = 0.04). While endocrine symptoms, fatigue, and anxiety improved at 6 months in those who lost ≥ 5%, differences were not significant vs. those who lost < 5%. There was no significant change within or between groups in sexual function, depression, or sleep. Findings at 12 months were similar, except pain improved in those losing ≥ 5%. CONCLUSIONS: These results support the benefits of weight loss in overweight/obese breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Weight management in breast cancer survivors may improve PF.
PURPOSE: In pre-planned observational analysis of the POWER-remote trial, we examined the impact of weight loss on patient-reported outcomes (PROs). We hypothesized a priori that survivors with ≥ 5% weight loss would have improved physical function (PF) at 6 months vs. those who did not. METHODS: Patients with stage 0-III breast cancer who completed local therapy and chemotherapy with BMI ≥ 25 kg/m2 were randomized to POWER-remote (telephone coaching; diet/activity tracking) or self-directed weight loss (booklet). Participants completed PROs at baseline, 6, and 12 months: PROMIS PF, pain, fatigue, anxiety, depression, sleep; FACT-endocrine symptoms; MOS-sexual function. Changes in PROs among those with ≥ 5% weight loss vs. those with < 5% were tested with multivariable mixed effect models, across randomized groups. RESULTS: Of 94 women who completed PROs, 84 and 69 participants were evaluable at 6 and 12 months, respectively. Regardless of intervention, PF improved in those with ≥ 5% weight loss vs. those with < 5% at 6 months (4.4 vs. 0.3 points; p = 0.02) and 12 months (3.6 vs. 0 points; p = 0.04). While endocrine symptoms, fatigue, and anxiety improved at 6 months in those who lost ≥ 5%, differences were not significant vs. those who lost < 5%. There was no significant change within or between groups in sexual function, depression, or sleep. Findings at 12 months were similar, except pain improved in those losing ≥ 5%. CONCLUSIONS: These results support the benefits of weight loss in overweight/obese breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Weight management in breast cancer survivors may improve PF.
Authors: Martina E Schmidt; Joachim Wiskemann; Andreas Schneeweiss; Karin Potthoff; Cornelia M Ulrich; Karen Steindorf Journal: Int J Cancer Date: 2017-11-13 Impact factor: 7.396
Authors: Ikuyo Imayama; Catherine M Alfano; Marian L Neuhouser; Stephanie M George; Ashley Wilder Smith; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Ching-Yun Wang; Catherine Duggan; Rachel Ballard-Barbash; Anne McTiernan Journal: Breast Cancer Res Treat Date: 2013-07 Impact factor: 4.872
Authors: Elia Biganzoli; Christine Desmedt; Marco Fornili; Evandro de Azambuja; Nathalie Cornez; Fernand Ries; Marie-Thérèse Closon-Dejardin; Joseph Kerger; Christian Focan; Angelo Di Leo; Jean-Marie Nogaret; Christos Sotiriou; Martine Piccart; Romano Demicheli Journal: Eur J Cancer Date: 2017-10-31 Impact factor: 9.162
Authors: Maret L Maliniak; Alpa V Patel; Marjorie L McCullough; Peter T Campbell; Corinne R Leach; Susan M Gapstur; Mia M Gaudet Journal: Breast Cancer Res Treat Date: 2017-08-31 Impact factor: 4.872
Authors: Kathleen A Meeske; Jane Sullivan-Halley; Ashley W Smith; Anne McTiernan; Kathy B Baumgartner; Linda C Harlan; Leslie Bernstein Journal: Breast Cancer Res Treat Date: 2008-02-24 Impact factor: 4.872
Authors: Ting Bao; Coby Basal; Christina Seluzicki; Susan Q Li; Andrew D Seidman; Jun J Mao Journal: Breast Cancer Res Treat Date: 2016-08-10 Impact factor: 4.872
Authors: Ahmed Hassoon; Yasmin Baig; Daniel Q Naiman; David D Celentano; Dina Lansey; Vered Stearns; Josef Coresh; Jennifer Schrack; Seth S Martin; Hsin-Chieh Yeh; Hadas Zeilberger; Lawrence J Appel Journal: NPJ Digit Med Date: 2021-12-09
Authors: Sevilay Tümkaya Yılmaz; Anneleen Malfliet; Ömer Elma; Tom Deliens; Jo Nijs; Peter Clarys; An De Groef; Iris Coppieters Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241